Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245906 | 0.93 | LTA4H (0.43) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL23151884 | 0.93 | LTA4H (0.43) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL1454708 | 0.82 | LTA4H (0.46) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL292317 | 0.77 | LTA4H (0.44) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL515722 | 0.77 | LTA4H (0.44) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL25265811 | 0.77 | LTA4H (0.44) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL1454452 | 0.77 | LTA4H (0.46) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| SCHEMBL5514895 | 0.77 | PPARG (0.43) | LTA4HALDH1A1 | |
| SCHEMBL28525750 | 0.77 | LTA4H (0.42) | LTA4HMLNRNR1I2ESR1NR3C1 | |
| Bromide SCHEMBL25222066 | 0.76 | LTA4H (0.43) | LTA4HMLNRNR1I2ESR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-10 | — | — | US | disclosed |
| US-7566808-B2 | Management of ophthalmologic disorders, including macular degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| CN-101282925-A | Management of ophthalmologic disorders, including macular degeneration | HARVARD COLLEGE (US) | 2008-10-08 | — | — | CN | disclosed |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-24 | — | — | US | disclosed |
| EP-1919858-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | The President and Fellows of Harvard College (US) | 2008-05-14 | — | — | EP | disclosed |
| CN-1997359-A | Treatment of ophthalmic diseases including macular degeneration | HARVARD COLLEGE (US) | 2007-07-11 | — | — | CN | disclosed |
| WO-2007019503-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1722766-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-30 | — | — | US | disclosed |
| WO-2005079774-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LTA4H 1172/4885MLNR 1567/4885NR1I2 1909/4885 |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LTA4H 1257/4885MLNR 1638/4885NR1I2 1924/4885 |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | ALDH1A2, PDE6C, PDE6B | LTA4H 1396/4885MLNR 1846/4885NR1I2 1159/4885 |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PDE6C, PDE6A, ALDH1A2 | LTA4H 1858/4885MLNR 1804/4885NR1I2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.